Thanyanan Reungwetwattana

Author

Also Known As

Oncogenic, Reungwetwattana T, T Reungwetwattana, T. Koyama, T. Reungwetwattana, THANYANAN REUNGWETWATTANA, Thanyanan Reungwetwattana

133

Publications

11.6K

Citations

H-Index

Concepts

All Affiliations

Ramathibodi Hospital Mahidol University Tongji University Shanghai Pulmonary Hospital Yonsei University

About

Thanyanan Reungwetwattana is an author at Ramathibodi Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	1.4K
2	Health Sciences	2	2	165
3	Engineering	1	1	24
4	Cell Biology	1	1	24
5	Hepatology	1	1	700

Thanyanan Reungwetwattana

Publications

10.4K

Citations

H-Index

Page 1

	Year	Citations
Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste, New England Journal of Medicine	2017	5K
Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard, New England Journal of Medicine	2019	2.7K
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer Thanyanan Reungwetwattana, Kazuhiko Nakagawa, Byoung Chul Cho, Journal of Clinical Oncology	2018	763
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma Milind Javle, Maeve A. Lowery, Rachna T. Shroff, Journal of Clinical Oncology Surgical OncologyPathologyPhase Ii StudyFgfr2 FusionsOncology	2017	700
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study Caicun Zhou, Sang-We Kim, Thanyanan Reungwetwattana, The Lancet Respiratory Medicine MedicineRandomised Phase 3ImmunologyPathologyAlectinib Versus Crizotinib	2019	268
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset Byoung Chul Cho, B. Chewaskulyong, Ki Hyeong Lee, Journal of Thoracic Oncology OncologyClinical TrialsCare Egfr TkiEgfrm Advanced NsclcMedicine	2018	132
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301 Byoung Chul Cho, Myung‐Ju Ahn, Jin Hyoung Kang, Journal of Clinical Oncology	2023	122
Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis Sendhilnathan Ramalingam, J.E. Gray, Yuichiro Ohe, Annals of Oncology OncologyMedicineFirst-line TreatmentPharmacotherapyCancer Treatment	2019	68
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC Viola W. Zhu, Yen-Ting Lin, Dong‐Wan Kim, Journal of Thoracic Oncology	2020	64
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors Nuttapong Ngamphaiboon, Grace K. Dy, Wen Wee, Investigational New Drugs Inhibitor EntinostatOncologyMedicinePathologyAdvanced Solid Tumors	2014	46

Page 1